Nominations are now open for the 2026 Fiercest Women in Life Sciences. | Who should be a 2026 Fiercest Woman in Life Sciences ...

Wave Life Sciences trades at 2.45x cash with a $1.2B market cap and no debt but faces intense competition across its RNA therapy pipeline. WVE-007 failed to meet FDA obesity drug benchmarks, causing a ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Carelon Research, a subsidiary of Elevance Health, and Manifold, an enterprise agent platform for life sciences, today announced a strategic partnership that gives life sciences researchers and data ...

Life Science Cares provides a platform for companies in the life sciences industry and their employees to make a difference. It makes impactful grants to community nonprofits that are implementing ...

How and where did the first forms of life arise? These are the main questions driving research at the Institute of Molecular ...

In this week’s edition of InnovationRx, we look at cancer breakthroughs from the ASCO conference, Clear’s move into healthcare, Harrison.ai’s U.S. expansion, and more. To get it in your inbox, ...

Life science layoffs have surged in the past few years. But here's why experts are hopeful for the industry's future.

Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health ('Wave” or 'Wave Life Sciences”), ...

This activity was supported by the National Academy of Sciences and the U.S. Department of Defense and the Army Research Office (Contract No. W911NF-23-D-0002). Any opinions, findings, conclusions, or ...

Understand the fundamentals that drive life. Do basic research that leads to medical breakthroughs and improvements in our world. Study the underlying chemistry of organisms and ecosystems. Help ...

Sellas Life Sciences (SLS) reported a Q2 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier. Two analysts polled by FactSet expected a loss of $0.05. As of ...